RAS与TP53共突变对结直肠癌肝转移术后ctDNA检出及早期复发的影响
该研究纳入105例接受根治性肝切除的结直肠癌肝转移(CLM)患者,术后180天内行ctDNA检测,中位随访28.3个月。术后ctDNA阳性与1年内早期复发独立相关(94% vs 49%;HR 11.8;p=0.003),RAS/TP53共突变使术后ctDNA阳性风险增加3倍以上。
要点
- 术后180天内ctDNA阳性是CLM肝切除后1年内复发的唯一独立危险因素(HR 11.8)。
- RAS/TP53共突变与术后ctDNA阳性独立相关(OR 3.30;p=0.019)。
- 术后ctDNA阳性(HR 2.04)与肝外转移(HR 2.45)均与无复发生存期较差独立相关。
核心结论
- CLM根治性肝切除术后ctDNA检出与1年或更早的早期复发相关,RAS/TP53共突变使术后ctDNA阳性风险增加3倍以上,提示肿瘤组织与循环突变谱分析具有互补作用。
研究设计与样本
- 纳入2013年1月至2020年6月间接受根治性肝切除且术后180天内行ctDNA分析的CLM患者,共105例,中位随访28.3个月;采用二代测序panel进行组织体细胞突变与ctDNA分析;排除原发肿瘤未切除及无1年随访者。
主要发现
- 105例中32例(30%)术后ctDNA阳性;ctDNA阳性者多发病灶比例高于阴性者(84% vs 55%,p=0.002),RAS/TP53共突变比例亦高于阴性者(47% vs 23%,p=0.018)。
- 多发病灶(OR 5.43;p=0.005)与RAS/TP53共突变(OR 3.30;p=0.019)与术后ctDNA独立相关。
- 围术期癌胚抗原水平无预后价值;术后ctDNA阳性(HR 2.04;p=0.011)与肝外疾病(HR 2.45;p=0.004)与无复发生存期较差独立相关。
- 校正肝外疾病、术前化疗、多发病灶、肿瘤活性≥50%及RAS/TP53共突变后,术后180天内ctDNA阳性是1年或更早复发的唯一独立危险因素(94% vs 49%;HR 11.8;p=0.003)。
关键数值与推荐
- 术后180天内ctDNA阳性者1年或更早复发率为94%,ctDNA阴性者为49%(HR 11.8;p=0.003)。
- RAS/TP53共突变者术后ctDNA阳性率为47%,无共突变者为23%(p=0.018)。
- 多发病灶者术后ctDNA阳性率为84%,单发病灶者为55%(p=0.002)。
临床怎么用
- 对CLM根治性肝切除患者可考虑术后180天内行ctDNA检测,以识别1年内早期复发高风险人群。
- 结合肿瘤组织RAS/TP53共突变状态与循环突变谱分析,可能有助于术后风险分层。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Circulating tumor DNA (ctDNA) is a promising biomarker for patients undergoing hepatectomy for colorectal liver metastases (CLM). We hypothesized that post-hepatectomy ctDNA detection would identify patients at highest risk for early recurrence of CLM. STUDY DESIGN: Patients with CLM who underwent curative-intent hepatectomy with ctDNA analysis within 180 days postoperatively (1/2013 and 6/2020) were included. Tissue somatic mutations and ctDNA analyses were performed by next-generation sequencing panels. Survival analyses determined factors associated with clinical recurrence 1 year or earlier after hepatectomy. Patients with primary tumors in situ and without 1-year follow-up were excluded. Median follow-up was 28.3 months. RESULTS: Of 105 patients, 32 (30%) were ctDNA positive (ctDNA+) after curative-intent hepatectomy. Compared with ctDNA-negative patients, ctDNA+ patients had multiple CLM (84% vs 55%, p = 0.002) and co-mutated RAS/TP53 (47% vs 23%, p = 0.018). Multiple CLM (odds ration (OR), 5.43; p = 0.005) and co-mutated RAS/TP53 (OR, 3.30; p = 0.019) were independently associated with post-hepatectomy ctDNA. Although perioperative carcinoembryonic antigen levels were not prognostic, postoperative ctDNA+ (hazard ratio (HR), 2.04; p = 0.011) and extrahepatic disease (HR, 2.45, p = 0.004) were independently associated with worse recurrence-free survival. After adjusting for extrahepatic disease, preoperative chemotherapy, multiple CLM, tumor viability of 50% or greater, and co-mutated RAS/TP53, ctDNA+ within 180 days was the only independent risk factor for recurrence 1 year or earlier after hepatectomy (94% vs 49%; HR, 11.8; p = 0.003). CONCLUSION: Postoperative ctDNA detection is associated with early recurrence 1 year or earlier after curative-intent hepatectomy for CLM, and RAS/TP53 co-mutations result in a more than 3-fold increased risk for postoperative ctDNA positivity. This highlights the complementary effect of tumor tissue and circulating mutational profiling for patients with CLM.
引用
- Nishioka Y, Chun YS, Overman MJ, et al. Effect of Co-mutation of RAS and TP53 on Postoperative ctDNA Detection and Early Recurrence after Hepatectomy for Colorectal Liver Metastases. J Am Coll Surg. 2022. PMID: 35290266. doi:10.1097/XCS.0000000000000093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。